LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: Cytomorphology of intraductal papillary neoplasm of the biliary tract.

    Canepa, Mariana / Yao, Ruisheng / Nam, Ga H / Patel, Nimesh R / Pisharodi, Latha

    Diagnostic cytopathology

    2019  Volume 47, Issue 9, Page(s) 922–926

    Abstract: Intraductal papillary neoplasms of the bile duct (IPNBs) are papillary epithelial proliferations with delicate fibrovascular cores within dilated bile ducts. They are thought to be premalignant lesions with potential to progress invasive tumors. To our ... ...

    Abstract Intraductal papillary neoplasms of the bile duct (IPNBs) are papillary epithelial proliferations with delicate fibrovascular cores within dilated bile ducts. They are thought to be premalignant lesions with potential to progress invasive tumors. To our knowledge, there are no prior descriptions of IPNB cytomorphology. A 58-year-old male presented with painless jaundice and elevated liver function tests was found to have an intraluminal mass within the left hepatic duct. A bile duct brushing diagnosed as "atypical cells present" showed a cellular specimen composed of papillary groups and linear strips of mostly cuboidal/columnar cells with mild atypia and vacuolated cytoplasm. A left hepatic lobectomy including extrahepatic bile ducts showed the mass consisted of papillary cores lined by pancreatobiliary-type epithelium with mild-to-severe atypia, consistent with IPNB with a focus suspicious for invasion. The cytomorphologic features described in the current case suggest intraductal papillary neoplasm but may not be specific since similar features could be seen in other bile duct tumors and even in nonneoplastic conditions such as stent or cholelithiasis. However, it is worthwhile to report papillary hyperplasia with atypia in common bile duct brushings in order to avoid a false-negative diagnosis, especially in the context of a filling defect by images which does not appear to be a stone.
    MeSH term(s) Bile Duct Neoplasms/metabolism ; Bile Duct Neoplasms/pathology ; Bile Ducts, Intrahepatic/metabolism ; Bile Ducts, Intrahepatic/pathology ; Carcinoma, Papillary/metabolism ; Carcinoma, Papillary/pathology ; Humans ; Male ; Middle Aged
    Language English
    Publishing date 2019-05-22
    Publishing country United States
    Document type Case Reports ; Journal Article
    ZDB-ID 632710-2
    ISSN 1097-0339 ; 8755-1039
    ISSN (online) 1097-0339
    ISSN 8755-1039
    DOI 10.1002/dc.24212
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Validation and performance comparison of three SARS-CoV-2 antibody assays.

    Paiva, Kimberly J / Grisson, Ricky D / Chan, Philip A / Huard, Richard C / Caliendo, Angela M / Lonks, John R / King, Ewa / Tang, Eric W / Pytel-Parenteau, Diane L / Nam, Ga H / Yakirevich, Evgeny / Lu, Shaolei

    Journal of medical virology

    2020  Volume 93, Issue 2, Page(s) 916–923

    Abstract: Serology testing of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is increasingly being used during the current pandemic of coronavirus disease 2019 (COVID-19), although its clinical and epidemiologic utilities are still debatable. ... ...

    Abstract Serology testing of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is increasingly being used during the current pandemic of coronavirus disease 2019 (COVID-19), although its clinical and epidemiologic utilities are still debatable. Characterizing these assays provides scientific basis to best use them. The current study assessed one chemiluminescent assay (Abbott COVID-2 IgG) and two lateral flow assays (STANDARD Q [SQ] IgM/IgG Duo and Wondfo total antibody test) using 113 blood samples from 71 PCR-confirmed COVID-19 hospitalized patients, 119 samples with potential cross-reactions, and 1068 negative controls including 942 pre-pandemic samples. SARS-CoV-2 IgM antibodies became detectable 3-4 days post-symptom onset using SQ IgM test and IgG antibodies were first detected 5-6 days post-onset using SQ IgG. Abbott IgG and Wondfo Total were able to detect antibodies 7 to 8 days post-onset. After 14 days post-symptom onset, the SQ IgG, Abbott IgG and Wondfo Total tests were able to detect antibodies from 100% of the PCR-confirmed patients in this series; 87.5% sensitivity for SQ IgM. Overall agreement was 88.5% between SQ IgM/IgG and Wondfo Total and 94.6% between SQ IgG and Abbott IgG. No cross-reaction due to recent sera with three of the endemic coronaviruses was observed. Viral hepatitis and autoimmune samples were the main source of limited cross-reactions. The specificities were 100% for SQ IgG and Wondfo Total, 99.62% for Abbott IgG, and 98.87% for SQ IgM. These findings demonstrated high sensitivity and specificity of appropriately validated SARS-CoV-2 serologic assays with implications for clinical use and epidemiological seroprevalence studies.
    MeSH term(s) Aged ; Antibodies, Viral/blood ; COVID-19/diagnosis ; COVID-19/immunology ; COVID-19 Serological Testing/methods ; Cross Reactions ; Female ; Humans ; Immunoassay/methods ; Immunoglobulin G/blood ; Immunoglobulin M/blood ; Luminescent Measurements/methods ; Male ; Middle Aged ; Reagent Kits, Diagnostic ; Sensitivity and Specificity
    Chemical Substances Antibodies, Viral ; Immunoglobulin G ; Immunoglobulin M ; Reagent Kits, Diagnostic
    Keywords covid19
    Language English
    Publishing date 2020-08-13
    Publishing country United States
    Document type Comparative Study ; Journal Article ; Validation Study
    ZDB-ID 752392-0
    ISSN 1096-9071 ; 0146-6615
    ISSN (online) 1096-9071
    ISSN 0146-6615
    DOI 10.1002/jmv.26341
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Validation and performance comparison of three SARS-CoV-2 antibody assays

    Paiva, Kimberly J / Grisson, Ricky D / Chan, Philip A / Huard, Richard C / Caliendo, Angela M / Lonks, John R / King, Ewa / Tang, Eric W / Pytel-Parenteau, Diane L / Nam, Ga H / Yakirevich, Evgeny / Lu, Shaolei

    J. med. virol

    Abstract: Serology testing of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is increasingly being used during the current pandemic of coronavirus disease 2019 (COVID-19), although its clinical and epidemiologic utilities are still debatable. ... ...

    Abstract Serology testing of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is increasingly being used during the current pandemic of coronavirus disease 2019 (COVID-19), although its clinical and epidemiologic utilities are still debatable. Characterizing these assays provides scientific basis to best use them. The current study assessed one chemiluminescent assay (Abbott COVID-2 IgG) and two lateral flow assays (STANDARD Q [SQ] IgM/IgG Duo and Wondfo total antibody test) using 113 blood samples from 71 PCR-confirmed COVID-19 hospitalized patients, 119 samples with potential cross-reactions, and 1068 negative controls including 942 pre-pandemic samples. SARS-CoV-2 IgM antibodies became detectable 3-4 days post-symptom onset using SQ IgM test and IgG antibodies were first detected 5-6 days post-onset using SQ IgG. Abbott IgG and Wondfo Total were able to detect antibodies 7 to 8 days post-onset. After 14 days post-symptom onset, the SQ IgG, Abbott IgG and Wondfo Total tests were able to detect antibodies from 100% of the PCR-confirmed patients in this series; 87.5% sensitivity for SQ IgM. Overall agreement was 88.5% between SQ IgM/IgG and Wondfo Total and 94.6% between SQ IgG and Abbott IgG. No cross-reaction due to recent sera with three of the endemic coronaviruses was observed. Viral hepatitis and autoimmune samples were the main source of limited cross-reactions. The specificities were 100% for SQ IgG and Wondfo Total, 99.62% for Abbott IgG, and 98.87% for SQ IgM. These findings demonstrated high sensitivity and specificity of appropriately validated SARS-CoV-2 serologic assays with implications for clinical use and epidemiological seroprevalence studies.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #671278
    Database COVID19

    Kategorien

  4. Article ; Online: Validation and performance comparison of three SARS‐CoV‐2 antibody assays

    Paiva, Kimberly J. / Grisson, Ricky D. / Chan, Philip A. / Huard, Richard C. / Caliendo, Angela M. / Lonks, John R. / King, Ewa / Tang, Eric W. / Pytel‐Parenteau, Diane L. / Nam, Ga H. / Yakirevich, Evgeny / Lu, Shaolei

    Journal of Medical Virology ; ISSN 0146-6615 1096-9071

    2020  

    Keywords Virology ; Infectious Diseases ; covid19
    Language English
    Publisher Wiley
    Publishing country us
    Document type Article ; Online
    DOI 10.1002/jmv.26341
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top